LinkedIn Profile

Access Rubius Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:rubiustherapeutics 9384498 Dec 3rd, 2020 12:00AM Rubius Therapeutics 10K 209.00 Open Biotechnology Dec 3rd, 2020 12:46PM Dec 3rd, 2020 12:46PM Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Our IND for RTX-240, our first oncology candidate for the treatment of solid tumors, has been cleared by the FDA. Additionally, we plan to file an IND for RTX-321 for the treatment of HPV-positive tumors by year-end. For more information, please visit us at www.rubiustx.com or follow us on Twitter. Open red blood cell, biotech, platform, oncology, autoimmune, science Open 399 Binney St, Suite 300 Cambridge Massachusetts US 02139 Rubius Therapeutics
private:rubiustherapeutics 9384498 Dec 2nd, 2020 12:00AM Rubius Therapeutics 10K 209.00 Open Biotechnology Dec 2nd, 2020 04:05PM Dec 2nd, 2020 04:05PM Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Our IND for RTX-240, our first oncology candidate for the treatment of solid tumors, has been cleared by the FDA. Additionally, we plan to file an IND for RTX-321 for the treatment of HPV-positive tumors by year-end. For more information, please visit us at www.rubiustx.com or follow us on Twitter. Open red blood cell, biotech, platform, oncology, autoimmune, science Open 399 Binney St, Suite 300 Cambridge Massachusetts US 02139 Rubius Therapeutics
private:rubiustherapeutics 9384498 Dec 1st, 2020 12:00AM Rubius Therapeutics 10K 209.00 Open Biotechnology Dec 1st, 2020 02:32PM Dec 1st, 2020 02:32PM Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Our IND for RTX-240, our first oncology candidate for the treatment of solid tumors, has been cleared by the FDA. Additionally, we plan to file an IND for RTX-321 for the treatment of HPV-positive tumors by year-end. For more information, please visit us at www.rubiustx.com or follow us on Twitter. Open red blood cell, biotech, platform, oncology, autoimmune, science Open 399 Binney St, Suite 300 Cambridge Massachusetts US 02139 Rubius Therapeutics
private:rubiustherapeutics 9384498 Nov 30th, 2020 12:00AM Rubius Therapeutics 10K 209.00 Open Biotechnology Nov 29th, 2020 08:34PM Nov 30th, 2020 03:23PM Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Our IND for RTX-240, our first oncology candidate for the treatment of solid tumors, has been cleared by the FDA. Additionally, we plan to file an IND for RTX-321 for the treatment of HPV-positive tumors by year-end. For more information, please visit us at www.rubiustx.com or follow us on Twitter. Open red blood cell, biotech, platform, oncology, autoimmune, science Open 399 Binney St, Suite 300 Cambridge Massachusetts US 02139 Rubius Therapeutics
private:rubiustherapeutics 9384498 Nov 28th, 2020 12:00AM Rubius Therapeutics 10K 209.00 Open Biotechnology Nov 28th, 2020 04:10PM Nov 28th, 2020 04:10PM Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Our IND for RTX-240, our first oncology candidate for the treatment of solid tumors, has been cleared by the FDA. Additionally, we plan to file an IND for RTX-321 for the treatment of HPV-positive tumors by year-end. For more information, please visit us at www.rubiustx.com or follow us on Twitter. Open red blood cell, biotech, platform, oncology, autoimmune, science Open 399 Binney St, Suite 300 Cambridge Massachusetts US 02139 Rubius Therapeutics
private:rubiustherapeutics 9384498 Nov 27th, 2020 12:00AM Rubius Therapeutics 10K 209.00 Open Biotechnology Nov 27th, 2020 12:35PM Nov 27th, 2020 12:35PM Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Our IND for RTX-240, our first oncology candidate for the treatment of solid tumors, has been cleared by the FDA. Additionally, we plan to file an IND for RTX-321 for the treatment of HPV-positive tumors by year-end. For more information, please visit us at www.rubiustx.com or follow us on Twitter. Open red blood cell, biotech, platform, oncology, autoimmune, science Open 399 Binney St, Suite 300 Cambridge Massachusetts US 02139 Rubius Therapeutics
private:rubiustherapeutics 9384498 Nov 26th, 2020 12:00AM Rubius Therapeutics 10K 209.00 Open Biotechnology Nov 25th, 2020 07:21PM Nov 26th, 2020 01:34PM Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Our IND for RTX-240, our first oncology candidate for the treatment of solid tumors, has been cleared by the FDA. Additionally, we plan to file an IND for RTX-321 for the treatment of HPV-positive tumors by year-end. For more information, please visit us at www.rubiustx.com or follow us on Twitter. Open red blood cell, biotech, platform, oncology, autoimmune, science Open 399 Binney St, Suite 300 Cambridge Massachusetts US 02139 Rubius Therapeutics
private:rubiustherapeutics 9384498 Nov 24th, 2020 12:00AM Rubius Therapeutics 10K 209.00 Open Biotechnology Nov 24th, 2020 02:43PM Nov 24th, 2020 02:43PM Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Our IND for RTX-240, our first oncology candidate for the treatment of solid tumors, has been cleared by the FDA. Additionally, we plan to file an IND for RTX-321 for the treatment of HPV-positive tumors by year-end. For more information, please visit us at www.rubiustx.com or follow us on Twitter. Open red blood cell, biotech, platform, oncology, autoimmune, science Open 399 Binney St, Suite 300 Cambridge Massachusetts US 02139 Rubius Therapeutics
private:rubiustherapeutics 9384498 Nov 23rd, 2020 12:00AM Rubius Therapeutics 10K 209.00 Open Biotechnology Nov 23rd, 2020 04:41PM Nov 23rd, 2020 04:41PM Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Our IND for RTX-240, our first oncology candidate for the treatment of solid tumors, has been cleared by the FDA. Additionally, we plan to file an IND for RTX-321 for the treatment of HPV-positive tumors by year-end. For more information, please visit us at www.rubiustx.com or follow us on Twitter. Open red blood cell, biotech, platform, oncology, autoimmune, science Open 399 Binney St, Suite 300 Cambridge Massachusetts US 02139 Rubius Therapeutics
private:rubiustherapeutics 9384498 Nov 22nd, 2020 12:00AM Rubius Therapeutics 10K 208.00 Open Biotechnology Nov 22nd, 2020 03:38PM Nov 22nd, 2020 03:38PM Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Our IND for RTX-240, our first oncology candidate for the treatment of solid tumors, has been cleared by the FDA. Additionally, we plan to file an IND for RTX-321 for the treatment of HPV-positive tumors by year-end. For more information, please visit us at www.rubiustx.com or follow us on Twitter. Open red blood cell, biotech, platform, oncology, autoimmune, science Open 399 Binney St, Suite 300 Cambridge Massachusetts US 02139 Rubius Therapeutics

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.